StoryFunding
Distalmotion raises $150M Series G led by Revival Healthcare Capital; Chas McKhann named executive chairman
Distalmotion closed a $150 million Series G to speed US adoption of Dexter, focused on ambulatory surgery centres, plus clinical and product development. Revival Healthcare Capital led with existing investors. Former Apollo Endosurgery and Silk Road Medical CEO Chas McKhann became executive chairman.
- $150M Series G led by Revival Healthcare Capital.
- Almost 3,000 patients treated with Dexter in Europe and the US at the time.
- Funds go to US commercial expansion, especially ambulatory surgery centres.